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Background
Melanoma vaccines have been designed to expand speci-
fic CD8+ T-cells, but melanoma-reactive helper T-cells
also can have antitumor activity. We previously observed
clinical activity of a vaccine incorporating 6 melanoma
helper peptides (6MHP), and found associations between
CD4+ T cell response and survival. With the present
study, in the spirit of personalized cancer immuno-
therapy, we define the relative immunogenicity and
HLA allele promiscuity of individual helper peptides, and
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identify helper peptide-mediated augmentation of mela-
noma-specific CD8+ T-cell response.
Methods
Thirty-seven patients with stage IIIB-IV melanoma were
vaccinated with 6MHP in incomplete Freund’s adjuvant.
The vaccines contained 6 peptides: gp10044-59 (first 3
amino acids: WNR), Tyrosinase56-70 (AQN), Tyrosi-
nase386-406 (FLL), Melan-A/MART-151-73 (RNG),
MAGE-A3281-295 (TSY), and MAGE-A1, 2,3,6121-134
(LLK). Peripheral blood mononuclear cells (PBMC) and
sentinel immunized nodes (SIN) were collected. CD4+
T-cell proliferation was assessed by thymidine uptake after
exposure to peptides. CD8+ T-cell response was assessed
by direct IFN-g ELIspot assay against 14 MHC class
I-restricted peptides.
Results
Vaccines induced CD4+ T cell responses to the 6MHP
pool in 78% (29/37) of patients in SIN and 57% (21/37) in
PBMC for an overall response rate of 81% (30/37), with
responses to an average of 2 peptides per patient. The two
most frequently immunogenic peptides were TSY at 49%
(18/37) and FLL at 32% (12/37). HLA restriction was not
limited to alleles originally described; for each peptide,
the proportion of immune responsive patients whose
HLA-DR expression matched those originally described
was similar to the proportion of patients with different
HLA-DR expression (unmatched, Figure 1). Vaccine-asso-
ciated CD8+ T-cell response was observed in 45% (5/11)
of patients, and three of these patients demonstrated
CD4+ T-cell response toward TSY.
Conclusions
The 6MHP vaccine has CD4+ T-cell immunogenicity
beyond known HLA-DR restrictions. Patients whose
tumors express tyrosinase, MAGE-A3, and several other
MAGE proteins may be ideal for vaccination with 6MHP.
The 4 most immunogenic peptides warrant further study,
perhaps in combination immune therapies.
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